Reassuring Safety Profile of Moxifloxacin | Zendy

Paul B. Iannini | Zendy; R Kubin | Zendy; C Reiter | Zendy; Glenn S. Tillotson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reassuring Safety Profile of Moxifloxacin

Author(s) -

Paul B. Iannini,

R Kubin,

C Reiter,

Glenn S. Tillotson

Publication year - 2001

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/319615

Subject(s) - medicine , moxifloxacin , safety profile , intensive care medicine , adverse effect , pharmacology , antibiotics , microbiology and biotechnology , biology

NOTE. Data from clinical trials are from [3]; data from postmarketing observationalstudies (PMOS) are on file. ADR, adverse drug reaction. Reprints or correspondence: Dr. Vladimir Krčmery, St. Elizabeth and University of Trnava Cancer Institute, Heyduková 10, 812 50 Bratislava, Slovak Republic (krcmery@spamba.sk). Clinical Infectious Diseases 2001; 32:1110–2 2001 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2001/3207-0021$03.00

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research